Table 1 Demographic characteristics of hydroxychloroquine users and non-users.
From: Hydroxychloroquine is neutral on incidental cataracts in patients with rheumatoid arthritis
Before PSM matched | p-value | After PSM matched | p-value | |||
|---|---|---|---|---|---|---|
HCQ (N = 822) n (%) | Non-HCQ (N = 486) n (%) | HCQ (N = 465) n (%) | Non-HCQ (N = 465) n (%) | |||
Age, years | 0.030 | 0.393 | ||||
20–65 | 735 (89.4) | 452 (93) | 425 (91.4) | 432 (92.9) | ||
≥ 65 | 87 (10.6) | 34 (7) | 40 (8.6) | 33 (7.1) | ||
Mean ± SD | 49.7 ± 13 | 47.3 ± 11.9 | 0.001* | 48.2 ± 12.4 | 47.9 ± 11.6 | 0.682 |
Gender | < 0.001* | 0.682 | ||||
Female | 616 (74.9) | 301 (61.9) | 294 (63.2) | 300 (64.5) | ||
Male | 206 (25.1) | 185 (38.1) | 171 (36.8) | 165 (35.5) | ||
Hypertension | 148 (18) | 75 (15.4) | 0.232 | 79 (17) | 75 (16.1) | 0.724 |
Hyperlipidemia | 54 (6.6) | 37 (7.6) | 0.473 | 38 (8.2) | 35 (7.5) | 0.715 |
Chronic liver disease | 66 (8) | 32 (6.6) | 0.338 | 37 (8) | 32 (6.9) | 0.532 |
Chronic kidney disease | 12 (1.5) | 6 (1.2) | 0.735 | 4 (0.9) | 6 (1.3) | 0.525 |
COPD | 35 (4.3) | 15 (3.1) | 0.286 | 12 (2.6) | 13 (2.8) | 0.839 |
Diabetes | 52 (6.3) | 27 (5.6) | 0.572 | 32 (6.9) | 26 (5.6) | 0.416 |
Uveitis† | 5 (0.6) | 5 (1) | 0.514 | 4 (0.9) | 5 (1.1) | 1 |
Glaucoma† | 9 (1.1) | 3 (0.6) | 0.551 | 1 (0.2) | 3 (0.6) | 0.624 |
Methotrexate | 406 (49.4) | 230 (47.3) | 0.470 | 227 (48.8) | 224 (48.2) | 0.844 |
Biologics | 97 (11.8) | 34 (7) | 0.005* | 38 (8.2) | 34 (7.3) | 0.624 |
Ophthalmology | 513 (62.4) | 292 (60.1) | 0.403 | 284 (61.1) | 280 (60.2) | 0.788 |
Corticosteroids | 678 (82.5) | 400 (82.3) | 0.935 | 383 (82.4) | 383 (82.4) | 1 |
